Arrowstreet Capital Limited Partnership raised its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 154.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 263,561 shares of the medical technology company's stock after acquiring an additional 160,106 shares during the quarter. Arrowstreet Capital Limited Partnership owned 1.11% of Inogen worth $2,417,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in INGN. AlphaQuest LLC acquired a new stake in shares of Inogen during the fourth quarter worth $43,000. Ieq Capital LLC acquired a new stake in Inogen in the 4th quarter worth about $94,000. Intech Investment Management LLC purchased a new stake in Inogen in the 4th quarter valued at about $94,000. Verition Fund Management LLC acquired a new position in shares of Inogen during the 3rd quarter valued at about $106,000. Finally, Summit Global Investments purchased a new position in shares of Inogen during the 4th quarter worth about $107,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.
Inogen Trading Down 0.8 %
NASDAQ INGN traded down $0.06 on Tuesday, hitting $7.26. 21,907 shares of the stock traded hands, compared to its average volume of 240,043. The stock has a 50-day moving average of $8.24 and a 200 day moving average of $9.21. Inogen, Inc. has a twelve month low of $6.40 and a twelve month high of $13.33. The company has a market capitalization of $195.28 million, a P/E ratio of -3.22 and a beta of 1.48.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on INGN shares. StockNews.com lowered Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research note on Wednesday, April 9th.
Read Our Latest Report on Inogen
Inogen Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
